Lucatumumab

From WikiMD.org
Jump to navigation Jump to search

Lucatumumab (pronounced loo-kah-too-moo-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Novartis, a Swiss multinational pharmaceutical company.

Etymology

The name "Lucatumumab" is derived from the Latin word "lucatus", meaning "illuminated", and "mumab", a suffix used in the International Nonproprietary Names (INN) for human monoclonal antibodies.

Mechanism of Action

Lucatumumab works by binding to a specific protein called CD40, which is found on the surface of many types of cancer cells. This binding triggers an immune response that can destroy the cancer cells.

Clinical Trials

Lucatumumab has been tested in several clinical trials for various types of cancer, including non-Hodgkin lymphoma and multiple myeloma. However, as of 2021, it has not yet been approved for use by any health regulatory authority.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski